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A B S T R A C T
Background: Human astroviruses (HAstV) comprise three phylogenetically compact and non-adjacent groups of
species including classical HAstV (HAstV-C) and the novel ones (HAstV-VA/HMO and HAstV-MLB). Of these,
HAstV-C is known to be responsible for gastroenteritis while the novel HAstV are associated with cases of
neurological disorders. Accurate detection of all known variants by (real-time) PCR is challenging because of the
high intra- and intergroup genetic divergence of HAstV.
Objectives: To evaluate published HAstV PCR assays in silico, design de novo real-time PCR assays that can detect
and discriminate three groups of HAstV, and apply those to patient samples to analyse the prevalence of HAstV
in stool and cerebrospinal fluid (CSF) specimens.
Study design: In silico evaluation of published PCR assays and design of real-time PCR assays for detection of
different subsets of HAstV was conducted within a common computational framework that used all astrovirus
full genome sequences from GenBank. The newly designed real-time PCR assays were evaluated in vitro and
applied to faecal samples (collected in January–May 2016) and cerebrospinal fluid specimens (2010–2016) from
patients in the Netherlands.
Results: Quantitative in silico evaluation of published PCRs is provided. The newly designed real-time PCR assays
can reliably assign all available HAstV genome sequences to one of the three phylogenetic groups in silico, and
differentiate among HAstV-specific controls in vitro. A total of 556 samples were tested using these PCR assays.
Fourteen fecal samples (2.5%) tested positive for HAstV, 3 of which could be identified as the novel HAstV-MLB
variants. No novel HAstV were found in CSF specimens.
Conclusion: Newly designed real-time PCR assays with improved detection of all known HAstV allowed the first-
time identification of novel astroviruses from stool samples in the Netherlands.
1. Background
Following the discovery of astrovirus in human stool [1], diverse
astroviruses were described in humans and other hosts. They were
classified in the family Astroviridae that is composed of two genera,
Mamastrovirus and Avastrovirus [2]. Human astroviruses (HAstV) belong
to the genus Mamastrovirus that includes four established species: Ma-
mastrovirus 1 (MAstV1; classic HAstV or HAstV-C, types 1–8),
Mamastrovirus 6 (MAstV6; known as HAstV-MLB, types 1–3), and clo-
sely relatedMamastrovirus 8 andMamastrovirus 9 (MAstV8 and MAstV9;
both known as HAstV-VA/HMO, types 1–5 and A–C, respectively), and
HAstV-BF34 a prototype of a putative separate species [3,4]. Collec-
tively, HAstV-MLB and HAstV-VA/HMO groups are often referred to as
novel HAstV.
Studies on prevalence and pathogenicity have shown HAstV-C to be
a causative agent of viral gastroenteritis, mainly affecting children,
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elderly, and immunocompromised patients [5]. Also, HAstV-MLB and
HAstV-VA/HMO have been identified in faecal samples obtained from
patients with gastroenteritis [6–8]. However, these novel astroviruses
have originally been described in association with severe neurological
infections and reported to be the causative agent of encephalitis/en-
cephalopathy and meningitis in immunocompromised patients [9–14].
Classical and novel HAstV have been monitored in different countries,
but their epidemiology remains poorly understood, particularly for the
novel HAstV (for reviews see references [2,15]).
Detection of HAstV-C and novel HAstV has been assisted by (real-
time) PCR assays developed in different laboratories [6,16–24], some of
which were included in diagnostic platforms for viral gastroenteritis.
2. Objectives
Our aim was to monitor the presence of HAstV in stool samples
submitted for diagnosis of viral gastroenteritis and CSF samples from
patients with encephalitis/meningitis of unknown aetiology. We em-
ployed the in-house bioinformatics platform (VEB-tool) to evaluate
accuracy of detecting HAstV by published (real-time) PCR assays and to
design de novo real-time PCR assays for discrimination between HAstV-
C, HAstV-MLB and HAstV-VA/HMO.
3. Study design
3.1. Genome sequences, multiple sequence alignments, and phylogeny of
astroviruses
A total of 147 complete genome sequences of viruses of the
Astroviridae family were retrieved from NCBI GenBank using HAYGENS
tool (version 1.0, http://veb.lumc.nl/HAYGENS; Sidorov, I.A. et al.,
manuscript in preparation) and downloaded into VirAliS platform [25].
One hundred and four complete genome sequences from the VRL di-
vision of GenBank with acceptable quality of sequencing (number of
non-ACTG symbols is less than 0.1% of the genome length and number
of calculated frame shifts in the coding part of genomes is not more
than 1) were selected for subsequent analysis. Multiple sequence codon-
based alignment (MSA) of these genomes was prepared in the VirAliS
platform as described elsewhere [26] using ClustalW [27], MUSCLE
[28], HMMER [29], and MAFFT software [30]. Phylogenetic relation-
ships between these viruses were reconstructed by FastTree [31] (ver-
sion 2.1.8), using MSA of three non-structural proteins (3CL, VPg, and
RdRp), of which the most variable columns were removed by the BAGG
tool of VirAliS.
3.2. In silico evaluation of existing and newly designed PCR assays
Published (real-time) PCR assays for the detection of astroviruses in
diagnostic settings were collected from literature and evaluated in silico
(Table 2). Briefly, the ability of an assay to detect a subgroup of HAstV
(“targets”) and other astroviruses (“non-targets”) was regarded as
sensitivity (SN) and selectivity (SL), respectively. They were calculated
taking in account sequence weights [32]. Probability of detection of
each virus was estimated based on probability of annealing of each PCR
oligo (primer or probe) to the viral DNA template using the nearest-
neighbour approach by calculating melting temperature (Tm) for all
oligo-template interactions. Location of the annealing sites for each
oligo-template interaction was defined by sites with the largest Tm. If
the PCR product length was not in the specified range (70–200 nu-
cleotides for all newly designed PCRs in this study and corresponding
values for published PCRs), the probability of detection for this tem-
plate was considered to be 0. When Tm values for both probe and
corresponding primer was close or Tm of the probe was at least 6 °C
higher than Tm of the corresponding primer, the probability of detec-
tion was multiplied by 0.5, and 1.0, respectively; linear interpolation
was used to adjust the detection probability for other values of Tm
difference. PCR conditions such as primer/probe and template con-
centration, PCR annealing temperature and salts concentration were
also taken into account.
3.3. In silico real-time PCR design
PCRs were designed in silico for selected subsets of HAstV and a
procedure that is summarized below. Briefly, the MSA of complete
genomes of a HAstV subset was analysed, and all conserved continuous
alignment regions (sets of no-gap columns) with length ranging be-
tween 18 and 28 nucleotides were considered as PCR oligo candidates.
Each PCR oligo candidate was tested for annealing with DNA copy of
genome sequences of the entire astrovirus-wide dataset using a set of
constraints imposed on several parameters for primers and probes in-
cluding: GC content, 30–80%; maximum number of consecutive iden-
tical nucleotides, 4; and maximum degeneracy, 50. After selecting PCR
oligo candidates, all possible combinations providing a PCR product of
length ranging between 70 and 200 nucleotides were considered as PCR
candidates and evaluated. For each candidate, PCR annealing tem-
perature value (Ta) was optimized in the range of 45–95 °C by max-
imizing PCR SN and SL values. After optimization of Ta, PCR candidates
were sorted by quality ((SN+ SL)/2). Next, PCR candidates having the
same value of quality were sorted by average PCR oligo degeneracy
(ascending order; the lower degeneracy, the more preferable the can-
didate), and calculated Ta value (descending order; the higher the Ta
the lower the probability of nonspecific oligo annealing). The PCR
candidate at the top of the list was considered as the best and used for in
vitro virus detection.
3.4. Control samples
In vitro evaluation of the HAstV real-time PCR assays designed in
this study was performed using a range of templates: RNA extracted
from viral cultures of HAstV-C types 1–8, plasmids of HAstV-MLB types
1–3 and HAstV-VA types 3–5, and, RNA from clinical samples infected
with HAstV-VA types 1 and 2 as well as HAstV-BF34, which were kindly
provided by the original authors [4,8,11]. In addition, a panel con-
sisting of 7 viral, 9 bacterial and 10 parasitical agents (supplementary
Table S1) were tested to determine the specificity of the assays.
3.5. Clinical samples
Remnant nucleic acids extracted from stool samples submitted for
diagnosing of viral gastroenteritis to the Department of Medical
Microbiology at the Leiden University Medical Center (LUMC) during
the period January–May 2016 were included in this study. This time-
frame reflects the period when HAstV-C are predominantly circulating,
as registered by the Dutch National Institute for Public Health and the
Environment (http://www.rivm.nl/Onderwerpen/V/Virologische_
weekstaten/Rapportages/Open_rapportages_virologische_weekstaten).
In addition, CSF specimens from patients with suspected meningitis or
encephalitis, based on clinical characteristics, were tested as well. No
selection was made based on age or other patient-characteristics and
only specimens with no proven aetiology (i.e. tested negative for all the
diagnostics performed) were included. Of all available CSF samples
received from 2010 to 2016, RNA was extracted and tested by real-time
PCR.
3.6. Viral RNA isolation
Remnant nucleic acids used in this study were extracted by adding
approximately 0.15 g of stool to 1ml S.T.A.R.-buffer (Roche
Diagnostics, Almere, the Netherlands) and precellys beads (Bertin
Technology, Rockville, USA), with subsequent vortexing at 2200 rpm
for 5min. After 5min incubation at room temperature, centrifugation
(1min at 18,407 g) was performed. From both the supernatant of the
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stool sample and CSF samples (no pre-treatment), RNA was extracted
using the MagnaPure96 system (Roche Diagnostics) with an input of
200 μl and an eluate volume of 100 μl. To every extraction, an aliquot of
equine arteritis virus (EAV) was added and used as an internal extrac-
tion and inhibition control [24].
3.7. Real-time PCR
For routine diagnosis of viral gastroenteritis in our setting, we use
the diagnostic multiplex real-time PCR assays that enables detection of
HAstV-C, sapovirus, norovirus GI, norovirus GII, adenovirus and rota-
virus [24]. For the purpose of this study it is labelled as diagn-HAstV.
For the current study, we used two real-time PCR assays designed to
recognize respective HAstV groups: monoplex VEB-HAstV-C and mul-
tiplex VEB-HAstV-VA/HMO and VEB-HAstV-MLB, with the latter also
including EAV PCR. Both assays were tested in a CFX96 detection
system (Bio-Rad, Veenendaal, the Netherlands), with a 25 μl reaction
mixture consisting of 6.25 μl of 4* TaqMan Fast Virus 1-step Mastermix
(Thermofisher Scientific, Landsmeer, the Netherlands), oligonucleo-
tides as listed in Table 1, and 10 μl of eluate. The cycling conditions
consisted of a reverse-transcriptase step of 5min at 50 °C, a denatura-
tion step of 2 s at 95 °C and subsequently 45 cycles of 15 s at 95 °C, 10 s
at 55 °C and 50 s at 60 °C. In every run, a positive amplification control
was tested containing either HAstV-C (RNA of a positive sample), VA-3
and MLB-1 (both plasmids).
3.8. Nucleotide sequence analysis
To determine the subtypes of the novel HAstV detected in this study,
the obtained PCR fragment was subjected to nucleotide sequence ana-
lysis by the dideoxy chain termination method, using 5μM of the
corresponding real-time PCR primers.
4. Results
4.1. In silico evaluation and design of HAstV PCR assays
Human astroviruses form three monophyletic non-adjacent groups
in a tree of the Astroviridae (highlighted as HAstV-C, HAstV-VA/HMO
and HAstV-MLB in Figure S1). Different subsets of these groups were
targeted by a range of PCR assays designed in our group [24] and other
studies [6,17–23], while a pan-astrovirus assay was also described
[16,33] (Fig. 1). We sought to evaluate these PCR assays in silico against
a genome database of astroviruses available on 21.04.2015 that did not
include HAstV-C type 7, using the original computational procedure
(see M&M). One genome was excluded from in silico evaluation (Gen-
Bank, AB308374.1, HAstV-C) due to its low sequencing quality that
may lead to underestimation of SN for some PCRs.
All subset-specific PCRs recognized genome sequences of its target
subset available at the time of PCR design, although recognition of new
variants may be less certain (Tables S2–S4). This uneven performance
was evident, when these PCRs were evaluated in silico against all
available genome sequences of the respective HAstV (sub)group
(Table 2). For the entire HAstV-C group (30 sequences), SN and SL of
seven published PCRs, developed to detect HAstV-C only, varied be-
tween 62.47% and 90.28%, and 90.98% and 100%, respectively
(Table 2). The diagn-HAstV assay showed the highest SN and SL
(90.28%/100%) but also demonstrated suboptimal detection of certain
types of HAstV-C (1, 2, 4 and 6), and, as expected, did not recognize
novel astroviruses (Fig. 2, Table S2). For HAstV-VA/HMO and HAstV-
MLB groups (both of nine sequences), SN of PCRs designed for detection
of viruses from these groups varied between 43.97% and 99.99%,
79.29% and 99.98%, respectively (Tables S3 and S4). None of these
PCRs sufficiently recognized BF34 subtype that is basal to the VA/HMO
clade. Due to substantial intra-group genetic diversities, the best per-
formed PCRs, which were designed by Cordey et al. [6], were composed
of several PCRs with low oligo degeneracy each directed against a
specific virus. SN of this PCR for HAstV-C, HAstV-VA/HMO, and HAstV-
MLB were 69.15%, 83.66% and 97.71%, respectively (evaluated as
multiplex PCRs for VA/HMO and MLB groups). In contrast to other
assays, Kapoor et al. [16] designed a PCR to recognize all HAstV, using
four sets of oligos with the degeneracy that ranges from 8 to 64. The SN
for three HAstV groups was estimated to be 92.49% (HAstV-C), 68.84%
(HAstV-VA/HMO), and 80.10% (HAstV-MLB) (Table 2).
This evaluation indicated that further advancement is required to
ensure that all known HAstV could be reliably recognized by real-time
PCR. We then found that designing a pan-astrovirus real-time PCR assay
with a single set of primers/probe was not possible due to the con-
siderable divergence of their genomes. In contrast, we identified be-
tween 20,000 and 200,000 candidate real-time PCR sets for sensitive
and selective recognition of HAstV-C, HAstV-VA/HMO and HAstV-MLB
groups, using alignments of 31, 9 and 9 complete genomes, respec-
tively. The best PCR sets with degeneracy of oligos ranging from 2 to 24
were selected to produce three group-specific assays whose sensitivity
and selectivity were>99% (Newly designed qPCRs, Table 2). At least
one degenerate oligo of each of these PCR sets overlapped with an oligo
or its complement of published PCRs, but the entire designed sets were
unique (Fig. 1).
4.2. In vitro evaluation of HAstV real-time PCRs
When tested in vitro, both diagn-HAstV and VEB-HAstV-C assays
detected HAstV-C type 1–8 isolates, as expected. Notably, VEB-HAstV-C
showed higher sensitivity compared to diagn-HAstV assay by re-
cognizing HAstV-C types 2, 6 and 7 with lower Cq-values (Table 3).
Both real-time PCR assays for the novel HAstV (VEB-HAstV-VA/HMO
and VEB-HAstV-MLB) enabled correct amplification and detection of
Table 1
Real-time PCR primers and probes used in this study.
PCR name (PCR
product location and






HAstV-Cs TAGTdTGyGCCGAyCCyA 900 nM
HAstV-Cas GGyCCArTCrAAyTCAAT 900 nM





HAstV-MLBs TTCCTAATmGGAATCGCCGTCGTA 700 nM








HAstV-VA/HMOs CTCCTTTGCTAyCGCATmCT 500 nM






EAVs CATCTCTTGCTTTGCTCCTTAG 200 nM
EAVas AGCCGCACCTTCACATT 200 nM
EAV-TQ-CY5as CGCTGTCAGAACAACATTATTGCCCAC 250 nM
nM: nanomols/l, s: sense, as: antisense.
Degenerate positions in oligo sequences: d=G or A or T; y= T or C; r=G or
A; k=G or T; w=A or T, m=A or C.
R.H.T. Nijhuis et al. Journal of Clinical Virology 108 (2018) 83–89
85
the plasmid materials containing HAstV-VA types 3–5 and HAstV-MLB
types 1–3 as well as the extracted RNA containing HAstV-VA types 1
and 2 and HAstV-BF34. Efficiency was assessed by testing a 10-fold
dilution series in duplicate for HAstV-C (type 1 only), HAstV-VA types
3–5 and HAstV-MLB types 1–3 and also the limit of detection was as-
sessed (Table 4).
All micro-organisms of the specificity panel tested negative in the
newly designed assays.
4.3. Monitoring the presence of astroviruses in clinical samples
A total of 556 faecal samples were collected from 461 different
patients and tested for the presence of HAstV. In three samples incon-
clusive results were obtained due to inhibition of the PCR (IC out of
range). In 14 stool samples obtained from 13 patients, HAstV were
detected with a range in Cq-values of 13.9–37.3. Co-infections, two
with norovirus genogroup II, one with rotavirus and one with adeno-
virus were demonstrated in four samples. HAstV-C were detected in 11
out of 14 astrovirus positive samples, of which 10 were also detected by
the diagn-HAstV assay that missed a sample with a Cq-value of 33.6.
Conversely, one specimen which remained negative by VEB-HAstV-C
was found positive by the diagn-HAstV assay (Cq-value 35.7). Further
sequence genotyping of the HAstV-C discrepancies was not performed
due to the high Cq-values. The remaining three HAstV detected be-
longed to HAstV-MLB and were obtained from two different patients.
Nucleotide sequence analysis revealed the closest match to HAstV-MLB
type 1 (MLB1) and type 2 (MLB2), respectively. No HAstV-VA/HMO
was detected in the faecal samples.
Two samples containing MLB1 were obtained from an im-
munocompromised child in January 2016 (Cq-value 22.3, submitted
because of watery diarrhoea) and March 2016 (Cq-value 21.1, obtained
because of increasing periods of diarrhoea). The latter showed a coin-
fection with adenovirus (Cq-value 29.3). The MLB2 (Cq-value 31.6)
containing stool sample was obtained from an immunocompetent child
suffering from chronic diarrhoea with a rotavirus co-infection (Cq-value
10).
A total of 142 CSF samples obtained from 136 patients were ana-
lysed with the VEB-HAstV-VA/HMO and VEB-HAstV-MLB multiplex
PCR. Fifty of the patients were suspected for encephalitis. None of the
tested specimens were positive for HAstV-VA/HMO or HAstV-MLB.
5. Discussion
Continuing discovery of new HAstV presents a perpetual challenge
to diagnostics of these viruses. To this end, we here introduce three
group-specific real-time PCR assays, which is the fewest feasible
number for covering the entire genetic diversity of HAstV. Their SN and
SL approached 100% in silico, both using the original and most recent
(as of 21.01.2017, data not shown) datasets of complete genome se-
quences of HAstV. These assays use degenerate oligos directed to
genome regions conserved in diverse viruses, so they may retain ability
to recognize also variants of these three groups that are yet to be de-
scribed.
We designed all three oligo sets without regard to published PCRs.
Yet, they overlap with others in the region around of the RdRp-Capsid
junction of approximately 1700 nucleotides (Fig. 1). This observation
reveals a link between the new and established PCRs that adds to their
credibility. We observed good correlation between results of our in silico
evaluation and those reported in vitro by the original authors of the
published PCR assays for comparable virus datasets as well as in our
comparison of VEB-HAstV-C versus diagn-HAstV. However, when the
published assays were evaluated in silico against the entire genome
sequence database, they demonstrated suboptimal SN and were out-
performed by the VEB-HAstV assays. Their SL was predominantly poor
(Table 2), since this parameter was not sufficiently optimized in PCR
design. On the other hand, established PCRs, especially designed by
Cordey et al., can detect and discriminate many HAstV, while VEB-
HAstV PCRs can assign HAstV only to a set of types [6].
Table 2
Results of in silico evaluation of the existing and newly designed PCR assays for detection of target viral groups of HAstV using dataset collected on April 21st, 2015.
PCR (reference) HAstV target viral subgroup(s) PCR oligos degeneracy value Sensitivity/selectivity (%) for detection of HAstVa
HAstV-C HAstV-VA/HMO HAstV-MLB
Published PCRs
Diagn-HAstV [24] C 4/3/1 90.28/100 0/78.94 0/78.92
Kapoor et al. [16]b C, VA/HMO, MLB 64/32/8/16/8 92.49/34.70 68.84/57.61 80.10/13.44
Cordey et al. [6] C 2/1/4 69.15/97.94 0/82.41 0/82.39
VA/HMOc 2/1/2;1/1/1;1/1/1;1/1/1 1.11/88.64 83.66/97.81 0.02/90.12
MLBc 2/2/1;1/1/1;1/1/1 9.00/70.82 7.02/73.65 97.71/97.48
Holtz et al. [17] MLB2 1/1/1 0/97.84 0/98.17 24.87/100d
Jiang et al. [18]g C 1/1/1 62.47/99.63 0/84.84 0/84.82
Noel et al. [19] C 1/1 66.30/98.75 0/83.72 0/83.72
Svraka et al. [21] C 1/2/1 64.82/95.76 0/81.50 0/81.49
Sakon et al. (22)f C 1/1 85.00/90.98 0/73.83 0/73.82
Smits et al. [23] VA1 1/1 0/94.63 42.40/100d 0/95.42
Finkbeiner et al. [20]e C 1/1 67.13/98.72 0/83.51 0/83.51
VA1 1/1 0/94.52 43.41/100d 0/95.33
MLB1 1/1 0/100 0/94.94 58.47/100d
Newly designed qPCRs (this study)
VEB-HAstV-C C 24/16/16 99.03/99.23 0/76.30 0/76.29
VEB-HAstV-VA/HMO VA/HMO 4/16/8 0/100 99.91/99.98 0/91.08
VEB-HAstV-MLB MLB 2/2/2 0/100 0/91.97 99.99/100
a values of sensitivity and selectivity for the viral group that includes or included in PCR target group are shown in bold.
b evaluated as multiplex PCR with 5 published oligos.
c PCRs for this target groups of astroviruses were evaluated as multiplex of 4 or 3 PCRs designed in [6] for detection of VA1/HMO-C/SG/PS/UK1, VA2/HMO-A,
VA3/HMO-B, and VA4 or MLB1, MLB2 (also evaluated separately, presented in(17)), and MLB2/3, respectively.
d target viruses for this PCR comprise a subgroup of the viral group for which selectivity is evaluated. Detailed analysis of the sensitivity for all shown target groups
for these PCRs in comparison with newly designed ones is represented in Fig. 2.
e only the second specific step of the two-step PCRs designed for detection of the corresponding targets in this study was used for evaluation.
f AC230/AC1′ primer combination was used for evaluation.
g Astrovirus specific PCR was evaluated separately from other non-Astrovirus PCRs.
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The prevalence of HAstV in fecal samples found in this study was
2.5% (14/556), which is comparable to that reported by a recent study
[6] (3.1%) and higher than found by us in preceding years in the same
time-period (laboratory information system data: 0.7%–2.2%). The
detection of HAstV-MLB1 and HAstV-MLB2, not targeted previously,
could explain this increase. While in our testing they accounted for
∼22% of all HAstV, their share in the Cordey et al. study was 50%, and
included VA2 type not present in our samples.
In the present study, all faecal specimens have been tested using
both the diagn-HAstV and the newly designed assays. They agreed on
10 positives and each additionally recognized an extra sample, both
with high Cq-values. These results were in agreement with the high
quality of these assays according to in silico evaluation. The false ne-
gative result obtained by the diagn-HAstV assay might be due to HAstV-
C type 2, 6 or 7, but further typing has not been performed and
therefore no definitive conclusion is possible.
Here, the first report of HAstV-MLB1 and HAstV-MLB2 types in the
Netherlands has been presented. Two MLB1-containing samples were of
high viral load and collected from the same patient over 3 months.
Although adenovirus (Cq-value 29.3) was identified in the later sample
as well, the higher HAstV-MLB1 load (Cq-value 21.1) pointed toward
HAstV as being most likely the main aetiological agent. Since novel
HAstV have also been detected in other specimens as urine and serum/
plasma [9,14], available plasma and urine samples of this patient were
tested but no HAstV-MLB was detected. The HAstV-MLB2 containing
stool also contained rotavirus (low Cq-value) which is a more likely
explanation of the gastroenteritis. No further samples of this patient
were available.
In several case reports, novel HAstV has been associated with en-
cephalitis or meningitis in patients. Therefore, we tested CSF samples
from patients with neurological symptoms without proven aetiology,
but no novel HAstV was detected in the 142 samples tested in this
study.
In conclusion, we present in silico evaluation of several published
HAstV PCR assays against 104 full genome sequences, representing the
entire known genetic diversity of HAstV, using a common computa-
tional framework. Its results are in good agreement with the published
in vitro evaluations by the original authors. We designed and evaluated
in vitro three new real-time PCR assays for improved detection of the
respective known phylogenetic groups of HAstV and their discrimina-
tion. These new PCRs assisted a survey of HAstV in patient specimens
that included the first-time identification of novel astroviruses from
stool samples in the Netherlands. We expect these assays to facilitate
detection of HAstV by other researchers.
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Table 3
Cq-values for detection of HAstV-C type 1–8 by VEB-HAstV-C and diagn-HAstV
PCR assays.
HAstV-C type VEB-HAstV-C diagn-HAstV dCq
1 27.0 26.0 −1.0
2 29.6 32.1 2.5
3 24.4 23.0 −1.4
4 24.9 24.3 −0.6
5 19.2 18.9 −0.3
6 20.4 24.5 4.1
7 18.8 25.8 7.0
8 21.3 21.4 0.1
dCq: delta Cq, difference in Cq-values between VEB-HAstV-C and diagn-HAstV
assays.
Table 4
Efficiency and limits of detection of HAstV real-time PCR assays.




101.1% 0.991 −3.296 nd
VEB-HAstV-VA/
HMO
VA3 93.3% 0.996 −3.494 10.37
VA4 94.4% 0.996 −3.463 12.79
VA5 112.4% 0.999 −3.056 14.43
VEB-HAstV-MLB MLB1 107.4% 0.994 −3.157 144.9
MLB2 106.6% 0.988 −3.173 7.57
MLB3 96.2% 0.992 −3.416 7.62
LoD: limit of detection, nd: not determined.
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